TY - JOUR
T1 - Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents
AU - Pipitone, Nicolò
AU - Olivieri, Ignazio
AU - Salvarani, C.
PY - 2012
Y1 - 2012
N2 - Objective: To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis. Methods: A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Behçet's disease. Results: A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence. Conclusions: These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.
AB - Objective: To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis. Methods: A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Behçet's disease. Results: A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence. Conclusions: These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.
KW - Biologic agents
KW - Large-vessel vasculitis
UR - http://www.scopus.com/inward/record.url?scp=84863759339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863759339&partnerID=8YFLogxK
M3 - Article
C2 - 22640657
AN - SCOPUS:84863759339
SN - 0392-856X
VL - 30
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
IS - SUPPL. 70
ER -